Enveda, a clinical-stage biotech company, secured $150 million in Series D funding. Premji Invest led the round, which also included new and existing investors such as Baillie Gifford and Kinnevik. This investment pushes Enveda to unicorn status, totaling $517 million in capital raised.
The company also enrolled its first patient in a Phase 1b clinical trial for ENV-294, its lead program targeting atopic dermatitis. Furthermore, Enveda appointed Dr. Mikael Dolsten, former Pfizer Chief Scientific Officer, to its Board of Directors. This Series D funding will advance multiple clinical programs into Phase 1b and Phase 2 trials.
Advancing AI-Driven Drug Discovery
Enveda utilizes a proprietary chemical sequencer, employing machine learning and metabolomics to decode chemistry in living systems. This platform accelerates drug discovery, delivering development candidates significantly faster and cheaper than industry averages. The company's pipeline includes 16 preclinical programs and four IND-enabling programs.
ENV-294, a first-in-class oral anti-inflammatory small molecule, was discovered entirely on Enveda's platform. This candidate demonstrates strong preclinical efficacy in inflammatory disease models. The company aims to address unmet medical needs in atopic dermatitis, asthma, inflammatory bowel disease, and obesity.
Enveda's rapid trajectory from seed to unicorn in five years outpaces many competitors like Recursion Pharmaceuticals and Exscientia. Its unique approach leverages billions of years of evolutionary intelligence.
